European Advanced Postgraduate Course in Classical and Molecular Cytogenetics 2018
Date: 5-13 March, 2018
Venue: Nîmes, France
Further information on the courses: Here
Inherited disorders of metabolism affecting the liver: management and outcome
Date: 8-9 March, 2018
Venue: Leuven, Belgium
21st Paris Summer School of Myology
Date: 18-23 June, 2018
Venue: Paris, France
Orphan Drugs and Rare Diseases Global Congress 2018: Europe
Date: 7-9 March, 2018
Venue: London, UK
The conference will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organisations, orphan drugs developers as well as regional and local manufacturers. For further information
RE(ACT) congress
Date: 7-10 March, 2018
Venue: Bologna, Italy
The RE(ACT) Congress – The International Congress on Research of Rare and Orphan Diseases aims to bring together world leaders and young scientist from a variety of breaking through the scientific field to present cutting-edge research, to discuss results and to exchange ideas. Patients and patient organizations will also be present to share their experience during this 4th edition co-organized in collaboration with E-RARE ERA-NET. For further information
International Symposium “Translational Science of Rare Diseases – From Rare to Care III
Date: 11-13 April, 2018
Venue: Tutzing, Germany
The meeting will bring high-profile scientists from around the world and will focus on how basic science on rare diseases can have an impact on the development of novel therapeutic strategies. For further information
26th annual Henry Kunkel society meeting in partnership with the journal of experimental medicine
Date: 12-14 April, 2018
Venue: Paris, France
Fundamental and clinical insights from the study of monogenic auto-inflammation and autoimmunity in humans. For further information
European Conference on Rare Diseases 2018: Registrations and call for poster abstracts open
Date: 10-12 May, 2018
Venue: Vienna, Austria
The European Conference on Rare Diseases 2018 (https://www.rare-diseases.eu) Co-organised by EURORDIS (www.eurordis.org), DIA, and for the first time Orphanet, the theme of this edition of the conference will be "Rare Diseases 360°: Collaborative Strategies to leave no-one behind". The programme, registration and call for poster abstracts have now been published. Poster submissions are open until 31st January 2018. For further information
4th World Congress: Rare Diseases and Orphan Products
Date: 11-12 June, 2018
Venue: Dublin, Ireland
The congress will serve as a bridge between researchers from academia and healthcare centres. The programme includes scientific sessions, plenary lectures, poster presentations, world-class exhibitions, diverse symposiums, highly enriched workshops and B2B meetings. For further information
15th Annual International Symposium on MPS and Related Diseases
Date: 2-4 August, 2018
Venue: San Diego, United States
This symposium is an opportunity for the MPS and related diseases community to share and exchange new information, learn about new breakthroughs in science and medicine, and develop strategies to keep us moving forward. As we look to an exciting future filled with opportunities on a global scale, we thank you for your hard work and dedication to eradicating these diseases and welcome you to the 15th International Symposium on MPS and Related Diseases. For further information
Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)
Date: 4-7 September, 2018
Venue: Athens, Greece
The theme of the scientific program is: “Old Roads, New Connections”. The objective of the symposium is to show how ‘OLD’ knowledge is being transformed and ‘NEW CONNECTIONS’ are being recognized. Giving a better understanding of the physiology and thus the pathophysiology of IEM’s and provide new diagnostic tools and new targets for treatment. For further information
The decisions concerning the focus of the present call are strongly motivated by the challenges related to research and treatment in rare cancers, which are intimately tightened to the low incidence of any single clinical-pathological entity currently listed among these cancers. On this basis, a network-based approach within the operating framework provided by TRANSCAN-2 could contribute to address compelling research questions in the area of interest. Indeed, the development and consolidation of consortia founded on international collaborations will allow to efficiently integrate resources spanning the entire continuum from diagnostics to therapeutics and maximize the efforts for collecting clinically annotated biological samples.
DEADLINE: 6 February, 2018
The Project Grant program is designed to capture ideas with the greatest potential to advance health-related fundamental or applied knowledge, health research, healthcare, health systems, and/or health outcomes. It supports projects with a specific purpose and a defined endpoint. The best ideas may stem from new, incremental, innovative, and/or high-risk lines of inquiry or knowledge translation approaches.
The Project Grant program will:
– support a diverse portfolio of health-related research and knowledge translation projects at any stage, from discovery to application, including commercialization;
– promote relevant collaborations across disciplines, professions, and sectors; and,
– contribute to the creation and use of health-related knowledge.
DEADLINES for the letter of intent: 6 February, 2018 and 6 March, 2018 for application
The ERA-Net “E-Rare” for research programmes on rare diseases has been extended to a third phase “E-Rare-3” (2014-2019) to further help in coordinating the research efforts of European countries in the field of rare diseases and implement the objectives of International Rare Disease Research Consortium (IRDiRC).
DEADLINES: 6 February, 2018: pre-proposals and 19 June, 2018 for full proposals.
The goal of FDA’s OOPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the product being developed will be superior to the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in or substantially contribute to, market approval of these products. Applicants must include in the application’s Background and Significance section documentation to support the assertion that the orphan disease or condition to be studied is a “rare disease or condition” and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.
The grants are available to any foreign or domestic, public or private, for-profit or nonprofit entity (including State and local units of government). Federal agencies that are not part of the Department of Health and Human Services (HHS) may apply. Agencies that are part of HHS may not apply. For-profit entities must commit to excluding fees or profit in their request for support to receive grant awards. Organizations that engage in lobbying activities are not eligible to receive grant awards.
DEADLINE: 7 February, 2018
The NCL Foundation is pleased to offer a new advancement training program. Thanks to great support from the Joachim Herz Stiftung they are able to announce another grant (100.000€). The so-called Neurodegeneration Award 2018 covers a postdoctoral fellowship salary for two years. The aim is to foster and improve synergies in research on the CLN3 childhood dementia and age-related neurodegeneration. Therefore, applicants must meet the following requirements:
Ideally, postdoctoral candidates should conduct a considerable part of their work in both laboratories. Laboratories interested in applying should first send a brief Letter of Intent. After acceptance, you will be asked to send in a full proposal. Whether you need help to find a collaborating partner do not hesitate to contact us.
You can send your application via email to Research@ncl-foundation.com
DEADLINE: 28 February, 2018
This programme intends to support only innovative clinical development for the compounds. This means that proposals for clinical development should not be considered in an indication which has been already tested (i.e. original primary indication or additional studies) or if there are already ongoing or planned clinical studies on identical or related disease indications with the compound or with a compound with overlapping mechanism of action that impacts the novelty of a given proposal.
DEADLINE: 28 February, 2018
The Scientific Advisory Board of the Jerome Lejeune Foundation invites you to submit your research project aiming at deciphering the pathophysiology of the cognitive deficits of patients, especially those (up to 50% of the total amount of the global grant) with trisomy 21 (Down syndrome) and linked pathologies as well as knowledge of the chromosome 21.
DEADLINE: application starts 15 January, 2018 and closes 5 March, 2018.
Cohorts are invaluable resources to obtain a detailed description of individual biological variations in connection with a variety of environmental, pathogenic, occupational, societal, and lifestyle determinants that influence the onset and evolution of diseases. Europe currently has some of the most valuable population and patient cohorts, including well-annotated clinical trial cohorts. Several large cohorts have also been developed in various parts of the world. Despite recent efforts to network cohorts, the level of integration needs to be escalated in order to optimise the exploitation of these resources, essential to underpin and facilitate the development of stratified and personalised medicine.
DEADLINE: 18 April, 2018
The research project call can be national or international, realised in public or private institutions. Funding may be accorded to all professionals who realised research on Rett syndrome or others such as:
- Students who are at the end of their PhD and/or in the continuity of their thesis defence for a period not exceeding 6 months
- For research time of Clinical Research Associates.
Doctoral and post-doctoral grants are not allowed.
Funding area:
- Molecular and biochemical aspects in typical and atypical forms of Rett syndrome
- Physiopathology of typical and atypical forms of Rett syndrome
- Amelioration of care and quality of life (including paramedical and educational aspects)
- Development of new therapeutic approaches
- Amelioration of diagnostic, care and evaluation of clinical aspect specific to Rett syndrome.
DEADLINE application: 15 March, 2018.
Substantial funding from the EU Framework Programmes for Research and Innovation has had an integrating effect in the field, and three consecutive ERA-NETs have built the base for close research collaboration between Member States. European Reference Networks (ERNs) established under the Directive on Patients' Rights in Cross-Border Healthcare will bring a major structuring effect on research and care by linking thematic expert centres across the EU.
There is a need to more efficiently bring the results of rare diseases research and innovation to patients in terms of new and optimised treatment options, diagnostic tools and integrated care, making sure that patients maximally benefit from the research and investments done at the EU and Member States levels.
DEADLINE: 18 April, 2018
IFCAH is a private fund, aimed to promote research on Congenital Adrenal Hyperplasia (CAH). In 2018, it launches its eighth call for proposals, in association with ESPE. A total amount of 350.000€ is associated to this program. Participation is open worldwide and should, if possible, include teams based in Europe. This restriction does not apply to projects aimed on gene or cellular therapies approach in CAH, which team can work all over the world.
DEADLINES: 15th January, 2018: Letters of intention and 23th April, 2018: Full application
The objective of FDA’s Orphan Products Natural History Grants Program is to support studies that advance rare disease medical product development through characterization of the natural history of rare diseases/conditions, identification of genotypic and phenotypic subpopulations, and development and/or validation of clinical outcome measures, biomarkers and/or companion diagnostics. Applicants must include in the application’s Background and Significance section documentation to support that the estimated prevalence of the orphan disease or condition in the United States (US) is less than 200,000 (or in the case of a vaccine or diagnostic, information to support that the product will be administered to fewer than 200,000 people in the US per year), and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.
DEADLINES: 31 August, 2018 for the letter of intent and 15 October, 2018 for the application
The objective of FDA’s Orphan Products Program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the product being developed will be superior to the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in/or substantially contribute to, market approval of these products. Applicants must include in the application’s Background and Significance section documentation to support the assertion that the orphan disease or condition to be studied is a “rare disease or condition” and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.
DEADLINE: 15 October, 2018
A book published by Jenny Reardon ‘The postgenomic condition: ethics, justice, and knowledge after the genome’ reflects the societal impact and analysis of the human genomic project occurring over the past two decades. The author presents a clear review of genomic advances and results since genomic emergence. Genomic participation and transparency giving value and meaning to sequencing data.
The content acquisition manager is responsible for collecting, integrating rare diseases content to the Orphanet database and to update its current content. S/he also has to write scientific articles to support the Orphanet work and publish new content about its advances in the rare diseases field. The job offer is in French and requires French/English speaking/writing skills to enable the content manager to interact with the whole Orphanet team members.